Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.

Eur Respir J · 2026 · PMC13347714 · PMID 41887669

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Nominally significant reductions in the risks of death, acute exacerbation of ILD or death, hospitalisation for respiratory cause or death and absolute decline in FVC % predicted >10% or death were also observed with both doses of nerandomilast compared with placebo.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.